Information  X 
Enter a valid email address

Fusion IP PLC (FIP)

  Print          Annual reports

Wednesday 10 April, 2013

Fusion IP PLC

Result of General Meeting

RNS Number : 0506C
Fusion IP PLC
10 April 2013



("Fusion IP" or the "Company")

Result of General Meeting


Further to the Company's announcement on 25th March 2013 regarding the placing to raise £20 million (the "Placing"), Fusion IP is pleased to announce that all resolutions were duly passed to approve the Placing at the General Meeting held this morning.   


The new ordinary shares being issued in connection with the Placing will be admitted to trading at 8.00 am on 11 April 2013.


10 April 2013


For further information please contact:

Fusion IP                                                                                                                                +44 (0) 114 275 5555

David Baynes, CEO

Stuart Gall, Press Relations                                                                                       


Cenkos Securities plc                                                                                                          +44 (0) 20 7397 8900

Elizabeth Bowman, Bobbie Hilliam (Corporate Finance)

Julian Morse (Sales)          


About Fusion IP


Fusion IP plc (Fusion) was established in 2002 to commercialise university-generated intellectual property. It has long-term exclusive agreements with two of the UK's leading research-intensive universities, the University of Sheffield and Cardiff University, giving it exclusive access to all the IP generated by their research departments. These exclusive agreements enable Fusion to identify world class IP and turn it into a commercial opportunity, either through the creation of a start-up company or a license.


Fusion currently owns shareholdings is over 20 portfolio companies, including significant shareholdings in Seren, Magnomatics, Phase Focus, MedaPhor, Asalus and Diurnal


In 2012 Fusion announced it's first major exit, when it sold its portfolio company Simcyp, a research-based business providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, to US based Certara LP for $32 million, a 200 fold return on its original investment.


For more information visit


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t